Mode
Text Size
Log in / Sign up

Electrical cardioversion and catheter ablation are safe and effective for arrhythmias in pregnant womenCatheter Ablation and Cardioversion Show Success for Pregnant Women

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider both electrical cardioversion and catheter ablation as safe and effective options for managing arrhythmias in pregnancy.

This narrative review evaluates the efficacy and safety of electrical cardioversion and catheter ablation for pregnant women with arrhythmias such as Atrial Fibrillation and AVNRT. The scope of the review is limited by a reliance on case reports, which may impact the generalizability of the findings.

The review synthesizes data showing an 89.7% success rate for electrical cardioversion in 58 patients and a 97.5% success rate for catheter ablation in 159 patients to restore sinus rhythm. Safety data noted 5 cases of preterm delivery following cardioversion and 2 cases of preterm delivery following ablation. Additionally, 2 cases of maternal-fetal mortality were reported in the cardioversion group.

While both procedures are effective, the authors note that evidence is largely based on case reports. The review concludes that both electrical cardioversion and catheter ablation are safe and effective treatment options during pregnancy. Clinical application should consider these findings as a baseline for managing arrhythmias in this high-risk population.

How this fits prior evidence

This narrative review addresses a gap in clinical management for pregnant patients with arrhythmias by evaluating procedural interventions. It complements prior evidence showing that catheter ablation reduces serious adverse events and unplanned hospitalizations by 20% and 47% in atrial fibrillation patients, though this specific review focuses on the safety profile during pregnancy.

This review looked at how doctors treat certain heart rhythm problems, such as Atrial Fibrillation and AVNRT, in women who are currently pregnant. The study reviewed cases involving two main treatments: electrical cardioversion and catheter ablation.

Results showed that 89.7% of the patients who received electrical cardioversion successfully returned to a normal heart rhythm. In the group that received catheter ablation, the success rate was even higher at 97.5%. Both methods were found to be effective ways to manage these conditions during pregnancy.

Safety is an important consideration for any treatment involving pregnant patients. The review noted some risks, including cases of preterm delivery and a few instances of maternal-fetal mortality in the cardioversion group. Because much of this information comes from individual case reports rather than large clinical trials, the evidence is still limited. Patients should talk to their doctors to decide which treatment is best for their specific situation.

What this means for you:
Both electrical cardioversion and catheter ablation are effective options for treating heart rhythms during pregnancy.

Common questions

Are these treatments safe during pregnancy?

Both electrical cardioversion and catheter ablation are considered safe and effective options for treating arrhythmias during pregnancy. While there were some reported risks, such as preterm delivery or maternal-fetal mortality in the cardioversion group, both procedures remain viable treatment paths.

How successful is catheter ablation for pregnant women?

The review found a 97.5% success rate for restoring a normal heart rhythm in patients who underwent catheter ablation. This high success rate makes it a strong option for managing specific conditions like Atrial Fibrillation or AVNRT during pregnancy.

How does electrical cardioversion compare to ablation?

Electrical cardioversion showed an 89.7% success rate in restoring sinus rhythm, while catheter ablation showed a 97.5% success rate. Both methods are effective, but the specific choice depends on the patient's needs and medical history.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
BackgroundDespite guideline recommendations, electrical cardioversion and catheter ablation remain underutilized for the management of pregnancy-associated arrhythmias, primarily due to persistent but unfounded safety concerns. However, delayed rhythm control may precipitate hemodynamic compromise, increasing risks of maternal cardiovascular instability and fetal distress. Herein, we report an illustrative case from our institution and provide a structured narrative review of electrical cardioversion and catheter ablation during pregnancy.MethodsWe present a case of recurrent arrhythmia in pregnancy that was refractory to standard therapies. The patient failed to respond to both radiofrequency ablation and electrical cardioversion. A search of Web of Science, Embase, and PubMed identified relevant studies using the terms pregnancy, electrical cardioversion, and catheter ablation. The quality of included studies was assessed using the Joanna Briggs Institute (JBI) appraisal tools. The primary efficacy endpoint was successful restoration of sinus rhythm, while the safety endpoint focused on maternal-fetal adverse events.ResultsA systematic review identified 19 studies (58 patients) reporting electrical cardioversion and 44 studies (159 patients) reporting catheter ablation during pregnancy, with success rates of 89.7% and 97.5%, respectively. Among pregnant women undergoing electrical cardioversion, there were 5 cases of preterm delivery and 2 cases of maternal-fetal mortality. The catheter ablation group had 2 cases of preterm delivery with no maternal-fetal mortality. Among different arrhythmia types, atrial fibrillation was the most common in the cardioversion group, while AVNRT predominated in the catheter ablation cohort.ConclusionBoth electrical cardioversion and catheter ablation are safe and effective treatment options during pregnancy. The available clinical evidence, though largely from case reports, consistently supports their use in this patient population.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.